被警示“可导致抑郁、自杀倾向”，孟鲁司特还能用吗？专家详解

Core Viewpoint - The National Medical Products Administration (NMPA) has decided to revise the labeling of Montelukast formulations, including warnings about potential neuropsychiatric adverse reactions such as depression and suicidal tendencies, which has raised concerns among parents and the public [1][2]. Group 1: Regulatory Changes - The NMPA's announcement aims to alert doctors and patients to monitor for neuropsychiatric side effects while using Montelukast, but it does not imply that the drug is unsafe or should not be used [2][3]. - The revision of the drug's labeling is intended to ensure that healthcare providers weigh the risks and benefits of the medication during treatment [2]. Group 2: Usage Guidelines - Montelukast is commonly used for treating asthma and allergic rhinitis, and its benefits may vary depending on the condition being treated [2][3]. - Patients, especially children, should be closely monitored for any changes in behavior or mood during treatment, and any concerning symptoms should be reported to a healthcare provider [3][4]. Group 3: Precautions for Specific Populations - Parents should inform doctors of any previous neuropsychiatric history before their children use Montelukast, and they should monitor their children's emotional and behavioral changes closely [4]. - Pregnant and breastfeeding women are advised to avoid Montelukast unless absolutely necessary, as safety studies in these populations are lacking [4].